AstraZeneca spins off autoimmune drugs into new biotech company

LONDON (Reuters) – AstraZeneca is spinning off six early-stage experimental drugs into a new $250 million standalone biotech company focused on severe autoimmune diseases.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *